HealthResJ, health, medicine, nursing, research https://ejournals.epublishing.ekt.gr/index.php/HealthResJ/sitemap

Epidemiological - clinical features of primary malignant brain tumors of patients who underwent surgical resection and / or radiotherapy

PDF
Published: Οκτ 1, 2015
DOI: https://doi.org/10.12681/healthresj.19286
Keywords:
Brain tumors histological classification Ki-67 radiotherapy chemotherapy
Anthoula Lagiou
RN, MSc, Head Nurse Pathological Department, General Anticancer and Oncologic Hospital of Athens "O Agios Savvas",Greece
Ioannis Papagiannopoulos
RN, MSc, Intensive Care Unit, General Anti-cancer and Oncologic Hospital of Athens "O Agios Savvas"
Nikoletta Margari
Assistant Professor,Department of Nursing,University of West Attica, Athens, Greece
Georgios Vasilopoulos
Assistant Professor,Department of Nursing,University of West Attica, Athens, Greece
Abstract

The aim of the present study was to describe the demographic characteristics of patients diagnosed with primary brain tumor, the clinical features and prognostic indicators of disease progression and treatment they received.
Methods: A retrospective descriptive study was conducted on a convenience sample of 47 patients who attended the radiotherapeutic department of General Hospital of Athens over three years, from May 2011 until May 2014.
For analysis used the statistical program SPSS 18.0.
Results: 59.6% of patients were male and 40.4% of patients were between 61 and 69 years. 85.1% of patients had glioblastomamultiforme and meningioma 8.5%. 57.5% of patients with glioblastomamultiforme were men and 50.0% of patients with meningioma. It was found that the patients with grade I-III were considerably higher percentage between 61 and 69 years as compared to patients with grade IV (p = 0,021). Patients with grade IV underwent chemotherapy significantly higher rate compared with patients with grade I-III. No significant difference was found in the course of radiotherapy among patients with grade IV and patients with grade I-III. Differed significantly Ki-67 among patients with grade IV and of patients with grade I-III patients with grade IV were higher Ki-67.
Conclusion: Glioblastoma multiforme (GBM) is the most frequently diagnosed intracranial malignant tumor in adults. Typical treatment for glioblastomas, with surgical resection followed by radiation and chemotherapy with temozolomide and anti - angiogenic therapy bevacizumab , have significantly improved the overall survival.

Article Details
  • Section
  • Research Articles

A) OPEN ACCESS POLICY

The journal "Health and Research Journal", follows an open access policy both for submission and accessing of articles.

Specifically the journal:

1. Claims no financial or any other gain from the author or authors of an article, neither for submission to the journal for publication, nor for revision and modification when peer reviewed.

2. Claims no financial or any other gain by articles' authors or by readers of the journal, for reading or downloading any article.

3. Reserves the right for the content and format of the printed article, not to be altered and to be used freely, preserving the form, the logo, the layout and the text as it is, a true copy of the file provided by the journal, with free access. (See also section C. Copyright Policy)

[The aforementioned apply equally for everyone and there is not any differentiation, restriction or other specific condition]

You can also ask more on the subject, from the editorial team of the journal, by sending mail to the journal. 

B) SELF-ARCHIVING POLICY

The journal "Health and Research journal", allows self-archiving of articles by the author or authors, under the following terms.

The journal allows:

1. The free self-archiving from the author, of a pre-printed article, at any stage of preparation it is, without limitations. As pre-printed, we consider the work that the author has not submitted yet to the journal and that certainly has not yet been peer reviewed.

2. The free self-archiving from the author, of the final, pre-printed article, that has been corrected and reviewed from the journal, with the expressed obligation to indicate that the article will be published by the journal "Health and Research Journal" and that it has been reviewed (or it is currently reviewed) by the journal's peer review process.

3. The free self-archiving from the author, of the final, printed article that has been published in the journal ""Health and Research Journal" with the expressed obligation to use only the printed pdf file of the journal (exact copy), that has the same logo, format and layout, as it is shared freely by the journal.

For more information on self-archiving policy, please contact the following link: OASIS (Open Access Scholarly Information Sourcebook)

You can also ask more on the subject, from the editorial team of the journal, by sending mail to journal.

C) COPYRIGHT POLICY

The journal "Health and Research Journal" reserves the rights for copyright of the content of the website and also the copyright of the articles published.

Specifically:

1. Does not allow any reproduction of part or whole of the content of the journal's website, if the original source is not explicitly stated.

2. Does not allow the usage, by third party, of journal's direct links to the pdf files (printed articles), if the original source is not explicitly stated (necessarily the name of the journal and optionally: year, volume, issue, pages).

3. All the members of the editorial board accept and comply with the national and international laws regarding copyrighted material, plagiarism and text-piracy, both for the content of the journal's website, as for the content of the published articles.

You can also ask more on the subject, from the editorial team of the journal, by sending mail to the journal.

D) PLAGIARISM POLICY

The journal "Health and Research Journal", reserves the right for detecting plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation, either with the use of special software or manually, at any stage before publication. For published articles by the journal, originality may also be checked after specific private complaint.

In case of plagiarism detection:

1. If the percentage of the manuscript's plagiarism is below 26%, the journal will contact and inform the author, asking for further revision and resubmission.

2. If the percentage of the manuscript's plagiarism is over 25%, the journal will contact and inform the author about the rejection of the article, without editorial review. Author is then advised to fully revise the manuscript before its new sumbission.

Downloads
Download data is not yet available.
References
Cance & Huether Mc, Pathophyciology: the biologic basis for disease in adults and children, Mosby (4th ed) St Louis, 2002.
Lemone P, Burke K, «Παθολογική – Χειρουργική Νοσηλευτική», εκδόσεις Λαγός, 3η έκδοση Αθήνα 2004.
Louis D.N, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P, The 2007 WHO classification of tumours of the central nervous system,
Acta Neuropathol 2007;14(2):97-109.
Rousseau A, Mokhtari K, Duyckaerts C, The 2007 WHO classification of tumors of the central nervous system - what has changed? Current Opinion in Neurology 2008
(6):720-7.
Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY, Primary brain tumours in adults, Lancet 2003;361: 323-331.
Harrison T, Εσωτερική Παθολογία, εκδόσεις Παρισιάνου, 16η έκδοση, Αθήνα 2005.
Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N
Engl J Med 2005;352(10):987-96.
Eom KY, Cho BJ, Choi EJ, Kim JH, Chie EK, Wu HG, Kim IH, Paek SH, Kim JS, Kim IA. The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and
Temozolomide on Malignant Glioma Cells in vitro and in vivo. Cancer Res Treat 2015 Jun 4.
Zhang W, Qiu XG, Chen BS, Li SW, Cui Y, Ren H, Jiang T. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core
pathway aberrations. Chin Med J (Engl) 2009;122(11): 1250-4.
Carlson JA , Reddy Κ , Gaspar LE , Ney D , Kavanagh BD , Damek D, et al. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol 2015;123(2):251-7.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline, Current Oncology 2014;
(3):e493-503.
Hainaut P. The tumor suppressor protein P53: a receptor to genotoxic stress that controls cell growth andsurvival. Current Opinion Oncology 1995; 7:76–82.
Tishler Rb, Calderwood SK, Coleman CN, Price BD. Increases in sequence-specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging
agents. CancerRes 1993; 53:2212–2216.
Donehower La, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Ice deficient for p53 are developmentally normal, but susceptible to spontaneous tumors 1992; 356:215–221.
Porth C, Pathophysiology: Concepts of altered health states (6thed), Philadelphia: Lippincott, 2002.
Bondy M, Scheurer M, Malmer B, BarnholtzSloan J, Davis F, Il’yasova D et al. Brain Tumor Epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
(BTEC), Cancer 2008; 113(7 Suppl): 1953– 1968.
Vida S, Richardson L, Cardis E, Krewski D, McBride M, Parent M-E, et al. Brain tumours and cigarette smoking: analysis of the INTERPHONE Canada case–control
study. Environ Health 2014; 13: 55.
Rehm J, Baliunas D, Guilherme L, Borges G, Graham K, lrving H, et al. The relation between different dimensios of alcohol consumption and burden of disease- an
overview. Addiction 2010;105(5):817-43.
Φερτάκης Α, Παθολογική Φυσιολογία, εκδόσεις Πασχαλίδης,2009.
Stranjalis G, Kalamatianos T, Stavrinou L, Mathios D, Koutsarnakis C, Tzavara C , et al. The Evangelismos hospital central nervous system tumor registry: Analysis of 1414
cases (1998-2009). Surg Neurol Int 2013; 4:23.
Friedlein K, Bozhkov Y, Hore N, Merkel A, Sommer B, Brandner S, et al. A new functional classification system (FGA/B) with prognostic value for glioma patients.
Sci Rep. 2015 Jul 21;5:12373.
Gao J, Wang Z, Liu H, Wang L, Huang G,Liposomeencapsulated of temozolomide for the treatment of gliomatumor: preparation, characterization and evaluation.Drug Discov
Ther 2015;9(3):205-12.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma.J Clin Oncol 2009; 27(28):4733-40.
Most read articles by the same author(s)